Target intelligence / Profile preview

Pseudolysin (LasB)

Target
LasB
Molecular classification
Enzyme, Metalloprotease, Zinc metalloendopeptidase, M4 family protease
01

Overview

Pseudolysin, commonly referred to as LasB elastase, is a potent extracellular zinc metalloprotease and a primary virulence factor secreted by the opportunistic pathogen Pseudomonas aeruginosa [1, 9]. It plays a multifaceted role in infection by degrading a wide range of host proteins, including elastin, collagen, and laminin, which leads to extensive tissue damage and facilitates bacterial invasion [5, 7, 15]. Beyond structural degradation, LasB subverts the host immune system by cleaving immunoglobulins, complement components, and various cytokines, thereby promoting immune evasion and persistent colonization [3, 7, 8]. It is also implicated in the regulation of biofilm formation and the activation of other bacterial enzymes [1, 14]. Because LasB is secreted into the extracellular environment, it is an accessible therapeutic target that does not require drugs to penetrate the complex Gram-negative bacterial cell wall [2, 6]. Current drug development efforts focus on pathoblockers—small-molecule inhibitors like phosphonates and thiols—that aim to attenuate virulence and enhance the efficacy of conventional antibiotics without inducing the selective pressure associated with traditional bactericidal agents [1, 2, 4].

Other names
LasB elastaseElastase BPseudomonas aeruginosa elastasePseudomonas elastaseZinc metalloendopeptidase
02

Mechanism of action

Inhibition of the zinc-dependent catalytic site of the metalloprotease to prevent the degradation of host tissues and immune components [1, 2, 5].

03

Biological functions

ProteolysisTissue degradationImmune evasionBiofilm formationNutrient acquisitionPathogenesis
04

Disease associations

InfectionCystic fibrosisChronic obstructive pulmonary diseaseKeratitisPneumoniaWound infection
05

Safety considerations

Off-target inhibition of human matrix metalloproteinases (MMPs)Therapeutic challenge of achieving complete inhibition to prevent residual immune modulation
06

Interacting drugs

N-mercaptoacetyl-Phe-Tyr-amide

4 more in the full profile.

07

Biomarkers

LasB protein levels in bloodLasB levels in sputumElastolytic activity in clinical samples

Beyond the preview

Go deeper on Pseudolysin (LasB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pseudolysin (LasB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call